BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 109 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $97,526 | +1240.2% | 38,548 | +9784.1% | 0.00% | – |
| Q1 2023 | $7,277 | -98.9% | 390 | -98.7% | 0.00% | -100.0% |
| Q4 2022 | $648,868 | +913.9% | 30,208 | +524.1% | 0.00% | – |
| Q2 2022 | $64,000 | -68.8% | 4,840 | -50.5% | 0.00% | – |
| Q1 2022 | $205,000 | +141.2% | 9,785 | +135.2% | 0.00% | – |
| Q4 2021 | $85,000 | -76.5% | 4,160 | -65.2% | 0.00% | – |
| Q3 2021 | $362,000 | -8.4% | 11,941 | -12.0% | 0.00% | – |
| Q2 2021 | $395,000 | -48.8% | 13,577 | -24.0% | 0.00% | -100.0% |
| Q1 2021 | $772,000 | -12.9% | 17,876 | -6.8% | 0.00% | -50.0% |
| Q4 2020 | $886,000 | -30.1% | 19,176 | -34.4% | 0.00% | -50.0% |
| Q3 2020 | $1,268,000 | -2.6% | 29,243 | +19.0% | 0.00% | -33.3% |
| Q2 2020 | $1,302,000 | +61.9% | 24,565 | -31.7% | 0.01% | -14.3% |
| Q1 2020 | $804,000 | – | 35,982 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 60,000 | $151,800 | 0.16% |
| XTX Topco Ltd | 33,605 | $85,021 | 0.02% |
| Beacon Pointe Advisors, LLC | 301,735 | $763,390 | 0.01% |
| AllSquare Wealth Management LLC | 4,527 | $11,453 | 0.01% |
| Virtus ETF Advisers LLC | 4,646 | $11,754 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 27,553 | $69,709 | 0.01% |
| SeaCrest Wealth Management, LLC | 16,550 | $41,872 | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 33,940 | $85,868 | 0.01% |
| Cutler Group LLC / CA | 4,000 | $50 | 0.01% |
| Capital Investment Advisory Services, LLC | 17,991 | $45,517 | 0.00% |